Effect of polymerised type I collagen on hyperinflammation of adult outpatients with symptomatic COVID‐19
Journal
Clinical and Translational Medicine
ISSN
2001-1326
2001-1326
Date Issued
2022
Author(s)
Méndez‐Flores, Silvia
Priego‐Ranero, Ángel
Azamar‐Llamas, Daniel
Olvera‐Prado, Héctor
Rivas‐Redonda, Kenia Ilian
Ochoa‐Hein, Eric
Pérez Ortiz, Andric Christopher
Rendón Macías, Mario Enrique
Rojas‐Castañeda, Estefano
Urbina‐Terán, Said
Septién‐Stute, Luis
Hernández‐Gilsoul, Thierry
Aguilar‐Morgan, Adrián Andrés
Fernández‐Camargo, Dheni A.
Olivares‐Martínez, Elizabeth
Hernández‐Ramírez, Diego F.
Torres‐Villalobos, Gonzalo
Furuzawa-Carballeda, Janette
Type
Resource Types::text::journal::letter to the editor
DOI
URL
Abstract
Dear Editor: Although dexamethasone is approved for the hyperinflammation treatment of hospitalised COVID-19 patients, non-hospitalised patients do not benefit from this therapy.1 A potential drug for treating COVID-19 patients is polymerised type I collagen (PTIC). A downregulator of pro-inflammatory cytokines, adhesion molecules (ELAM-1, VCAM-1, and ICAM-1), cyclooxygenase (Cox)-1 enzyme and the collagenases expression through the modulation of transcription of factor NF-kB.2-6 The intramuscular or subcutaneous administration of PTIC to patients with active RA (Phase II studies) improved the count of swollen joints and morning stiffness; 57% of patients achieved an ACR score of 50, and 30% had disease remission with this therapeutic combination. PTIC was safe and well-tolerated in long-term treatment, without adverse effects. © Clinical and Translational Medicine